LATEST NEWS: Scientists edit embryos' genes to study early human development - LONDON, Sept 20 (Reuters) - British scientists have used a genome editing tool known as CRISPR/Cas9 to knock out a gene in embryos just a few days old, testing the technique's ability to decipher key gene functions in early human development.
LATEST NEWS: CDC issues guidance on storm recovery - NEW YORK (Reuters Health) - The Centers for Disease Control and Prevention has been using multiple channels to get the word out about post-storm safety to residents of areas still reeling from the effects of recent hurricanes.
LATEST NEWS: Comedian's sharp criticism detours Republican U.S. healthcare drive - WASHINGTON (Reuters) - The latest Republican drive to replace Obamacare was detoured on Wednesday by popular comedian Jimmy Kimmel's biting criticism of the proposal and accusation that one of its chief sponsors "lied right to my face" about it, while President Donald Trump embraced the bill.
LATEST NEWS: Alnylam's genetic disease drug succeeds key study, shares soar - (Reuters) - Alnylam Pharmaceuticals Inc's drug to treat a rare genetic disease cleared a key study, moving the company closer to filing a marketing application for the drug, which is part of a new class of medicines that block disease-causing proteins.
LATEST NEWS: Novartis's Rydapt wins EU approval for AML, other diseases - ZURICH (Reuters) - Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals the medicine secured in April.
LATEST NEWS: GSK's new triple lung drug beats other modern inhalers in study - LONDON (Reuters) - GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease (COPD) patients more than other modern treatments.